Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome
Pediatric Neurology, 08/10/2009
Degrauw RS et al.– For children and adolescents with Tourette syndrome treated >1 yr with neuroleptic agents, findings show that weight gain is not excessive for all cases. Methods- Study of effects of neuroleptic agents on body ... mass index for age and sex (body mass index Z scores) in matched cohort of 16 neuroleptic-treated and 29 nonneuroleptic-treated children and adolescents with Tourette syndrome
- Assessment of growth parameters in 45 children, age 5-15 yrs, treated for 3-yr average (range, 1-6) with low doses ... neuroleptic treatment, age, duration, and treatment X duration interactions on changes in Z score
- Repeat measures analysis of variance for time course of changes
Results- Mean first-yr weight gain differed significantly (13.5 kg neuroleptic vs 3.2 kg nonneuroleptic ... li>
- Long-term Z score changes did not differ significantly
- Repeated measures analysis of Z scores differed significantly by treatment, related to first-year changes only
[more...]
|
Neuroleptic malignant syndrome from central nervous system insult: 4 cases and a novel treatment strategy
Journal of Neurosurgery: Pediatrics, 09/03/2009
|
Wait SD et al. – Neuroleptic malignant syndrome is a rare, life–threatening disorder that can occur without the administration of neuroleptic medications. Alleviation of any CNS ... insult is the first order of treatment. Some patients with persistent symptoms of NMS may benefit from intrathecal delivery of baclofen.
[more...]
|
Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients
Indian Journal of Psychiatry, 08/21/2009
|
Sarkar P et al. – The prevalence of NMS was 0.45%. All were young males, suffering from manic episode with psychotic symptoms and managed with oral and parentral neuroleptic medicines.
[more...]
|
Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients
International Clinical Psychopharmacology, 08/17/2009
in these patients. Methods- Compared 93 individuals treated with atypical antipsychotics, 27 treated with conventional neuroleptics and 33 untreated patients.
Results- Did not find any difference according to sex, but the mean body mass index varied ... antipsychotics than in patients who received conventional neuroleptics (P=0.035).
- The TFEQ disinhibition and DEBQ emotional eating scores tended to change among the three types of treatment.
- Patients with metabolic syndrome (19%) had lower DEBQ external eating scores (P=0.044) and
[more...]
|
Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication
Psychiatry Research, 08/04/2009
|
Halacheva K et al. – Significantly higher levels of aCL antibodies of both isotypes were found in schizophrenic patients versus controls. In patients IgM–aCL positivity was ... values were not associated with neuroleptic treatment and psychotic symptoms, as measured by the Positive and Negative Syndrome Scale and the Pentagonal Structural Model of Schizophrenic Symptoms.
[more...]
|
Malignant Catatonia in a Patient with Bipolar Disorder, B12 Deficiency, and Neuroleptic Malignant Syndrome: One Cause or Three
Journal of Psychiatric Practice, 10/01/2009
|
Lewis L et al. – The authors discuss the differential diagnosis of catatonia as reflecting a high likelihood of underlying mood disorder; the evaluation and management of malignant catatonia and malignant neuroleptic syndrome; and the
[more...]
|
The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro
World Journal of Biological Psychiatry, 08/26/2009
|
Dietrich–Muszalska A et al. – The obtained results indicate that the difference in action of tested drugs on platelet aggregation may dependent on the various
[more...]
|
Negative symptoms in neuroleptic-naive patients with first-episode psychosis correlate with QEEG parameters
Schizophrenia Research, 08/19/2009
|
Gschwandtner U et al. – The present results confirm the correlation of negative symptoms with power of slow frequency bands. In addition to previous studies in chronic schizophrenia
[more...]
|
Gray Matter in First-Episode Schizophrenia Before and After Antipsychotic Drug Treatment. Anatomical Likelihood Estimation Meta-analyses With Sample Size Weighting
Schizophrenia Bulletin, 09/21/2009
|
ndash;limbic, and temporal morphological abnormalities are present in the early stage of schizophrenia and are unrelated to the effects of neuroleptic treatment, chronicity, and duration of illness. There may be dynamic effects of treatment on striato–limbic and temporal, but not frontal
[more...]
|
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/2009
|
Ballard C et al. – Large prospective, randomized, placebo–controlled trials are needed to establish the role of agents other than neuroleptics as clinical therapies for the treatment of BPSD and studies are urgently needed to evaluate BPSD treatments in non–Alzheimer dementias
[more...]
|
